Company Description

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally.

The company provides NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.

Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.

The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

Neuronetics, Inc.

Country	United States
Founded	2003
IPO Date	Jun 28, 2018
Industry	Medical Devices
Sector	Healthcare
Employees	658
CEO	Daniel Reuvers

Contact Details

Address: 3222 Phoenixville Pike Malvern, Pennsylvania 19355 United States
Phone	877 600 7555
Website	neurostar.com

Stock Details

Ticker Symbol	STIM
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001227636
CUSIP Number	64131A105
ISIN Number	US64131A1051
SIC Code	3841

Key Executives

Name	Position
Daniel L. Reuvers	Chief Executive Officer, President and Director

Latest SEC Filings

Date	Type	Title
May 5, 2026	10-Q	Quarterly Report
May 5, 2026	8-K	Current Report
Apr 10, 2026	EFFECT	Notice of Effectiveness
Apr 9, 2026	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 9, 2026	DEF 14A	Other definitive proxy statements
Apr 8, 2026	SCHEDULE 13D/A	Filing
Apr 6, 2026	8-K	Current Report
Mar 31, 2026	SCHEDULE 13D	Filing
Mar 19, 2026	144	Filing
Mar 19, 2026	144	Filing

View All SEC Filings